Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation
- 31 July 1995
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 26 (1), 41-46
- https://doi.org/10.1016/0272-6386(95)90151-5
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patientsAmerican Journal of Kidney Diseases, 1995
- Optimization of Iron Therapy in Hemodialysis Patients Treated with rHuEPOSeminars in Dialysis, 1994
- Intravenous Versus Subcutaneous Dosing of Epoetin: A Review of the LiteratureAmerican Journal of Kidney Diseases, 1993
- Optimizing Epoetin Therapy in End-Stage Renal Disease: The Case for Subcutaneous AdministrationAmerican Journal of Kidney Diseases, 1993
- Androgens Potentiate the Effects of Erythropoietin in the Treatment of Anemia of End-Stage Renal DiseaseAmerican Journal of Kidney Diseases, 1991
- Iron status in patients receiving erythropoietin for dialysis-associated anemiaKidney International, 1989
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinThe New England Journal of Medicine, 1987
- A Clinical Evaluation of Serum Ferritin as an Index of Iron StoresThe New England Journal of Medicine, 1974